English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Unfortunately, none of these compounds has high selectivity for these channels. Mibefradil has been marketed worldwide for the treatment of hypertension and angina for a short period before it was withdrawn due to its pharmacokinetic and pharma- codynamic interactions with some other drugs such as terfen- adine, astemizole, cisapride, cyclosporine, tricyclic antidepre- ssants. 4 Mibefradil binds to skeletal muscle L-type calcium channels and brain voltage-gated sodium channels with disso- ciation constants of 2.3 and 17 nM, respectively. 5 It also can block potassium and chloride channels. 6 Obviously, this makes it not an ideal tool for in vitro or in vivo studies on T-type channels. Therefore, more potent and selective blockers are required to study the fundamental function of T-type channel and the related pathophysiological diseases such as epilepsy, neuronal pain, hypertension, congestive heart failure, and can- cer. 7-8

Multi-Functional 3,4-Dihydroquinazoline Derivative as T-Type Calcium Channel Blocker: Pharmacokinetics and Anti-Tremor Activity